ATE243998T1 - Liposomformulierung von 5-beta steroiden - Google Patents

Liposomformulierung von 5-beta steroiden

Info

Publication number
ATE243998T1
ATE243998T1 AT96933929T AT96933929T ATE243998T1 AT E243998 T1 ATE243998 T1 AT E243998T1 AT 96933929 T AT96933929 T AT 96933929T AT 96933929 T AT96933929 T AT 96933929T AT E243998 T1 ATE243998 T1 AT E243998T1
Authority
AT
Austria
Prior art keywords
liposome formulation
5beta
dhea
steroid
lipid
Prior art date
Application number
AT96933929T
Other languages
English (en)
Inventor
Joseph Rubinfeld
Elliott L Fineman
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Application granted granted Critical
Publication of ATE243998T1 publication Critical patent/ATE243998T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT96933929T 1995-10-12 1996-09-27 Liposomformulierung von 5-beta steroiden ATE243998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54208395A 1995-10-12 1995-10-12
PCT/US1996/015507 WO1997013500A2 (en) 1995-10-12 1996-09-27 LIPOSOME FORMULATIONS OF 5β STEROIDS

Publications (1)

Publication Number Publication Date
ATE243998T1 true ATE243998T1 (de) 2003-07-15

Family

ID=24162270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933929T ATE243998T1 (de) 1995-10-12 1996-09-27 Liposomformulierung von 5-beta steroiden

Country Status (10)

Country Link
US (1) US6436435B1 (de)
EP (1) EP0801557B1 (de)
JP (1) JPH10508322A (de)
CN (1) CN1173815A (de)
AT (1) ATE243998T1 (de)
CA (1) CA2208215A1 (de)
DE (1) DE69628909T2 (de)
HU (1) HUP9801834A3 (de)
IL (1) IL121070A (de)
WO (1) WO1997013500A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
AU7736300A (en) * 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (fr) 1999-10-13 2004-04-30 Oreal Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
EP1223941B1 (de) * 1999-10-25 2008-11-05 Hollis-Eden Pharmaceuticals Inc. Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
JP2004537506A (ja) * 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症を治療するためのある種のステロイドの使用
AU2002332426A1 (en) * 2001-07-25 2003-02-17 Richard A. Haase Processes and apparatus for the manufacture of polynuclear aluminum compounds and disinfectants, and polynuclear aluminum compounds and disinfectants from such processes and apparatus
FR2827766A1 (fr) * 2001-07-27 2003-01-31 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
FR2827765B1 (fr) * 2001-07-27 2003-09-19 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
EP1499338A4 (de) * 2002-05-01 2008-06-18 Arthur Schwartz 7-hydroxy-16alpha-fluor-5-androsten-17-one und 7-hydroxy-16alpha-fluor-5-androstan-17-one und ihre derivate
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8268269B2 (en) 2006-01-24 2012-09-18 Clearvalue Technologies, Inc. Manufacture of water chemistries
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2376097A4 (de) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amidbasierte peptid-prodrugs der glucagon-superfamilie
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
ES2662710T3 (es) 2010-05-24 2018-04-09 Swedish Oat Fiber Ab Dispersión acuosa que comprende galactolípidos y método de producción de la misma
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4518595A (en) 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
US4666898A (en) 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
US4507289A (en) 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
CA1264668C (en) 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
DE3689769T2 (de) 1985-07-05 1994-07-21 Liposome Co Inc Multilamellare liposome mit verbesserter einschliessungswirkung.
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE3626421A1 (de) * 1986-08-05 1988-02-11 Recipe Pharma Vertriebs Gmbh & Peptid, pharmazeutisches mittel und verwendung desselben zur stimulierung der lipolyse
US5006517A (en) 1987-12-01 1991-04-09 Progenics, Inc. Treatment of Prader-Willi syndrome
US5041287A (en) 1989-05-22 1991-08-20 Terry L. Driggers Sprayable composition using acetone solvent
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU668934B2 (en) 1992-04-10 1996-05-23 Hisamitsu Pharmaceutical Co., Inc. Liposome composition
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen

Also Published As

Publication number Publication date
IL121070A0 (en) 1997-11-20
DE69628909T2 (de) 2003-12-24
CA2208215A1 (en) 1997-04-17
HUP9801834A3 (en) 2000-06-28
DE69628909D1 (de) 2003-08-07
US6436435B1 (en) 2002-08-20
WO1997013500A3 (en) 1997-05-29
EP0801557A2 (de) 1997-10-22
WO1997013500A2 (en) 1997-04-17
CN1173815A (zh) 1998-02-18
HUP9801834A2 (hu) 1999-02-01
EP0801557B1 (de) 2003-07-02
JPH10508322A (ja) 1998-08-18
IL121070A (en) 2004-06-20

Similar Documents

Publication Publication Date Title
DE69628909D1 (de) Liposomformulierung von 5-beta steroiden
ATE212234T1 (de) Hormonpflaster
NL193616B (nl) Gesubstitueerde androsta-1,4-dieen-3,17-dionen, alsmede farmaceutische preparaten die dergelijke verbindingen bevatten.
PT1090029E (pt) 14,15-ciclopropanoesteroides da serie dos 19-norandrostanos, processo para a sua producao e preparacoes farmaceuticas contendo estes compostos
ATE304845T1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
NO981944D0 (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
EA200000711A1 (ru) 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, СПОСОБ ПОЛУЧЕНИЯ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ, СОДЕРЖАЩИХ ЭТИ 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, И ИХ ПРИМЕНЕНИЕ ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
AU7072596A (en) Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
NO20065784L (no) Steroidforbindelser og anvendelse av slike
CA2069483A1 (en) Steroid sulphatase inhibitors
PT1003490E (pt) Sistema terapeutico transdermico (tts) para administracao de hormonas sexuais esteroides
AU4101589A (en) Pharmaceutical preparations which can be applied transdermally, containing sterolins and/or spiroketalins
AU5805096A (en) Transdermal therapeutic system (TTS) for the administration of testosterone
DK0742214T3 (da) I hjerte-kar-systemet aktive, nye seco-D steroider samt farmaceutiske præparater indeholdende sådanne
SU1240038A1 (ru) 3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью
DE69603793D1 (de) Kardioaktive 17-Hydroxyiminoalkyl- und 17-Hydroxyiminomethylalkenyl-Steroid-Derivate, ein Verfahren zu ihrer Herstellung und pharmazeutische Präparate davon
PT1090028E (pt) 14,15-ciclopropano-androstanos insaturados processo para a sua preparacao e composicoes farmaceuticas que contem estes compostos
ATE240343T1 (de) Darstellung von esterderivaten von steroiden
EP0172034A3 (de) Mikrobiologischer Abbau von Steroiden
EP1210874A4 (de) "knockout"-tier für das alpha-tocopherol-transportprotein
FI946082A0 (fi) Menetelmä steroidisten perasyyliglykosidien valmistamiseksi
LV10902A (lv) Metode holesterina un ta metabolitu izdalisanai no biologiskiem audiem
BR9814717A (pt) "método de preparação de esteróides 16alfa, 17alfa-dialquilados"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties